Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

By
Noshin Noorjahan
-
0
94
Intellia Therapeutics, Inc. announced that the US FDA has cleared the company’s IND application for NTLA-2001 for the treatment of ATTR amyloidosis with cardiomyopathy.
[Intellia Therapeutics, Inc. (GlobeNewswire)]
Press Release